A novel vaccine, Circumvent® CML, is ‍now available to swine producers in Argentina, offering simultaneous protection against three key pathogens: Porcine Circovirus type 2 (PCV2), Mycoplasma hyopneumoniae,⁣ and ‍ Lawsonia intracellularis. The vaccine is administered via a single, ‍2-milliliter intramuscular injection starting at three weeks of age, representing a important advancement ⁣in preventative swine healthcare.

Simplified Immunization for Reduced Stress

Circumvent® CML is designed to simplify immunization protocols, reducing the⁤ number of injections required for young pigs. This reduction minimizes animal stress, optimizes ‍farm labor, and lowers the potential risks ⁣associated with⁢ handling and repeated procedures.‍ The formulation focuses on combining proven efficacy with⁣ improved animal welfare and operational efficiency.

Backed⁢ by Extensive Research

The vaccine’s effectiveness is supported by ten international registration studies,leveraging established antigens and adjuvants⁢ already utilized in other recognized vaccines. This robust scientific foundation positions Circumvent® CML as an‍ innovative solution for disease prevention in swine production.

Boosting Productivity and ‍Animal Welfare

According to industry experts,Circumvent® CML ⁢represents ⁢a ‍change in how pig health is managed in Argentina. The triple protection offered in ‍a single dose⁤ delivers convenience, value, and targeted results, ultimately contributing ⁤to both enhanced animal welfare and increased farm productivity.

The introduction of Circumvent® CML sets a new benchmark for⁣ pig health management in Argentina, integrating scientific innovation to address critical production challenges.